Filing Details
- Accession Number:
- 0001437749-19-006477
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-04-03 16:30:35
- Reporting Period:
- 2019-04-01
- Accepted Time:
- 2019-04-03 16:30:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1586049 | Oxford Immunotec Global Plc | OXFD | In Vitro & In Vivo Diagnostic Substances (2835) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1592286 | Peter Wrighton-Smith | C/O Oxford Immunotec Global Plc 94C Innovation Drive Abingdon, Oxfordshire X0 OX14 4RZ | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2019-04-01 | 31,669 | $0.00 | 445,138 | No | 4 | A | Direct | |
| Ordinary Shares | Disposition | 2019-04-01 | 10,000 | $16.64 | 435,138 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2019-04-01 | 600 | $17.21 | 434,538 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Share Option (Right to Buy) | Acquisiton | 2019-04-01 | 67,959 | $0.00 | 67,959 | $16.42 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 67,959 | 2029-04-01 | No | 4 | A | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2015, as amended.
- The price reported for the sales on April 1, 2019 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.25 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
- The price reported for the sales on April 1, 2019 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.20 to $17.25 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
- Options granted under Issuer's 2013 Share Incentive Plan
- Options will become exercisable ratably on the anniversary of the vesting start date from January 1, 2020 through January 1, 2023.
Billionaire Hedge Funds
